Olanzapine-induced glucose dysregulation

Annals of Pharmacotherapy

Volumn 34, Issue 7-8, 2000, Pages 865-867

  Bettinger, Tawny L ^a,b   Mendelson, Stacy C ^c   Dorson, Peter G ^a   Crismon, M Lynn ^a,b  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b Texas Dept Mental Hlth Mental R   (United States)

^c Austin State Hospital   (United States)

Author keywords

Atypical antipsychotics; Diabetes mellitus; Olanzapine

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE;

ADULT; ARTICLE; CASE REPORT; DEPRESSION; DIABETES CONTROL; DIABETES MELLITUS; DISEASE EXACERBATION; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; METABOLIC DISORDER; PRIORITY JOURNAL; WEIGHT GAIN;

EID: 0033914006     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.19327     Document Type: Article

References (16)

1. Markowitz JS, Brown CS, Moore TR. Atypical antipsychotics part I: pharmacology, pharmacokirietics, and efficacy. Ann Pharmacother 1999; 33:73-85.
2. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacologie characteristics? A review of the evidence. Neuropsychopharmacoloay 1998;18:63-101.
3. Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, et al. Olanzapine versus haloperidol in the treatment of schizophrenia, schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-65.
4. Sanger TM, Lieberman JA, Tohen M, Beasley C Jr, Tollefson GD. Olanzapine versus haloperidol in first episode psychosis. Am J Psychiatry 1999;156:79-87.
5. Olanzapine. In: McEvoy GK, ed. American Hospital Formulary Service. Bethesda, MD: American Society of Health System Pharmacists, 1999.
6. Fertig MK, Brooks VG, Shelton PS, English CW. Hyperglycemia associated with olanzapine. J Clin Psychiatry 1998;59:687-9.
7. Penn JV, Martini J, Radka D. Weight gain associated with risperidone (letter). J Clin Psychopharmacol 1996;16:259-60.
8. Popli AP, Konicki PE, Jurjus GJ, Fuller MA, Jaskiw GE. Clozapine and associated diabetes mellitus. J Clin Psychiatry 1997;58:108-11.
9. Hagg S, Joelsson L, Mjorndalt T, Spigset O, Oja G, Dahlqvist R. Prevalence of diabetes and impaired glucose tolerance in patients with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry 1998;59:294-9.
10. Wirshing DA, Spellburg BJ, Erhart SM, Marder SR, Wirshing WC. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998;44: 778-83.
11. Ober SK, Hudak R, Rusterholtz A. Hyperglycemia and olanzapine (letter). Am J Psychiatry 1999;156:970.
12. Lindenmayer JP, Patel R. Olanzapine-induced ketoacidosis with diabetes mellitus (letter). Am J Psychiatry 1999;156:1471.
13. Goldstein LE, Sporn J, Brown S, Kim H, Finkelstein J, Gaffey GK, et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 1999;40:438-43.
14. Gatta B, Rigallaeu V, Gin H. Diabetic ketoacidosis with olanzapine treatment (letter). Diabetes Care 1999;22:1002-3.
15. Sobel M, Jaggers ED, Franz MA. New-onset diabetes associated with the initiation of quetiapine treatment (letter). J Clin Psychiatry 1999;60: 556-7.
16. Naranjo CA, Busto U, Sellers P, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.